Track topics on Twitter Track topics that are important to you
The latest approval for Fragmin is for the blood thinner to be used for reducing symptomatic venous thromboembolism (VTE) in pediatric patients, aged one month and older. The
The post Pfizer’s blood clot drug Fragmin gets FDA approval for pediatric patients appeared first on Pharmaceutical Business review.NEXT ARTICLE
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...